Company Overview
Trevi Therapeutics, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to developing and commercializing investigational therapies specifically for the treatment of chronic cough in patients suffering from idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The company functions within the healthcare sector, specifically the biotechnology industry, which implies a focus on high-risk, high-reward research and development aimed at addressing unmet medical needs through innovative drug discovery rather than manufacturing or selling established consumer goods. As of the latest available data, the company holds a market capitalization of $1.36B, employs 34 individuals, and reports no annual revenue figures in its trailing twelve-month period. The absence of reported revenue combined with a substantial market cap of $1.36B indicates that the company's valuation is driven primarily by the potential of its clinical pipeline and future commercial prospects rather than current cash flow generation, positioning it as a growth-stage entity where investor capital is allocated to bridge the gap between laboratory development and market entry.
Financial Health
The company reports a net income of $-42,759,000 and an EBITDA of $-49,184,000 over the trailing twelve months, while revenue for this period is not available in the provided data. The significant gap between the reported net income of $-42,759,000 and the EBITDA figure of $-49,184,000 reveals a cost structure heavily weighted by non-operating expenses or specific accounting adjustments, as the net loss is slightly smaller in magnitude than the EBITDA loss, suggesting interest or tax impacts are mitigating the operational burn rate. Free cash flow stands at $-27,859,000, indicating that the company is currently consuming cash to fund its operations and research activities, which limits immediate financial flexibility but is typical for clinical-stage biotechnology firms in the development phase. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, a figure that reflects the company's current lack of commercial sales volume rather than an inefficient operational model, as margins are only calculable once revenue is generated. The balance sheet shows a cash balance of $188.26M against total debt of $753,000, resulting in a debt-to-equity ratio of 0.41, which suggests a highly conservative leverage profile with minimal outstanding obligations relative to equity. The current ratio is an exceptionally high 19.66, indicating that the company possesses more than 19 times the liquid assets required to cover its short-term liabilities, providing a robust buffer against liquidity risks despite the ongoing cash burn. Return on Equity is -30.2% and Return on Assets is -20.3%, metrics that reveal management is currently utilizing the company's capital base to generate losses, a standard characteristic of early-stage biotechnology companies where returns are reinvested into R&D rather than distributed to shareholders.
Valuation Assessment
The P/E Ratio (TTM) is not available due to the lack of net income, while the forward P/E is listed as -18.81, a negative figure that implies the market is pricing in future earnings potential rather than relying on historical profitability. The price-to-book ratio is 7.44, indicating that the market values the company at more than seven times its book value, which suggests a significant premium assigned to the company's intellectual property and clinical pipeline assets over its tangible book equity. The price-to-sales ratio and EV/EBITDA are not available or are negative (-23.89 for EV/EBITDA), meaning traditional valuation multiples based on sales or earnings cannot be applied, forcing reliance on asset-based or clinical milestone valuations instead. The stock has a 52-week high of $14.39 and a 52-week low of $4.85, and without the specific current trading price provided in the facts, the relative position within this range cannot be calculated, but the spread between these levels highlights the volatility inherent in the biotechnology sector. The beta value is 0.99, which indicates that the stock's price volatility moves in tandem with the broader market, lacking the significant defensive or aggressive characteristics often seen in small-cap biotechnology stocks.
Growth & Income
The revenue growth and earnings growth rates are not available for the year-over-year period, preventing a direct comparison of whether earnings are growing faster or slower than revenue. The dividend yield is not available, and the payout ratio is 0.0%, which confirms that the company does not pay dividends to shareholders. Since the company does not pay dividends, the 0.0% payout ratio is sustainable because no cash is being distributed, and instead, the company reinvests all available earnings and cash reserves into its research and development efforts to advance its therapeutic candidates. The overall growth and income profile is characterized by a complete absence of current income generation and reported growth metrics, with the company's strategy focused entirely on capitalizing its market cap of $1.36B and cash reserves of $188.26M to achieve future clinical milestones rather than delivering immediate financial returns to investors.